Oxford GlycoSciences Plc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (201)	3/28/2002 2:12:48 PM
From: tuck	Read Replies (1) of 469

Nigel, In poking around Gaucher's websites, I notice that neurological problems are associated with type 2 & 3 forms, which are supposed to be rarer than type 1. Do we have any idea what types are represented in this trial? If they are all type 1s -- for which I have seen no reference to neurological symptoms -- OGS' saying that neurological problems are associated with the disease would seem disingenuous. Supposedly the details of the presentation were to be made available on the website, but I haven't found them, and have found the website to be difficult to navigate -- maybe it's just my ongoing browser problems. Could you have a look? Diarrhea might be managed, considering Vevesca will cost 1/3 as much as Cerezyme (and has applications in other indications), but neurological problems are indeed another kettle of fish. Hope I haven't been stupid taking the company at its word on this issue. TIA & Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next